| Elizabeth Bollenbacher, DO | |
|
417 State St, Ste 400, Bangor, ME 04401-6630 | |
| (207) 942-6096 | |
| (207) 973-8857 |
| Full Name | Elizabeth Bollenbacher |
|---|---|
| Gender | Female |
| Speciality | Pulmonary Disease |
| Experience | 26 Years |
| Location | 417 State St, Bangor, Maine |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1417985508 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RP1001X | Internal Medicine - Pulmonary Disease | 1944 (Maine) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Eastern Maine Medical Center | Bangor, ME | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Eastern Maine Medical Center | 2062315161 | 577 |
News Archive
SynCardia Systems, Inc. continues to set records with the implantation of the year's 150th SynCardia temporary Total Artificial Heart on Nov. 26, 2013.
CANCER RESEARCH UK scientists have developed a system to identify faulty or missing genes that could prevent specific chemotherapy regimes from working. This opens the doors for targeted breast cancer treatment, according to research published in the Lancet Oncology* today (Monday).
The new head of the Department of Veterans Affairs said Monday he is working to streamline the VA's sprawling bureaucracy, simplify the process for veterans to receive care and hire thousands of new doctors and nurses.
The anti-anginal medication ranolazine was shown to be safe in regard to certain outcomes but did not reduce the risk of major cardiovascular events such as death, heart attack or recurrent ischemia following acute coronary syndromes, according to a study in the April 25 issue of JAMA.
› Verified 8 days ago
| Entity Name | Eastern Maine Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1790789147 PECOS PAC ID: 2062315161 Enrollment ID: O20040128000088 |
News Archive
SynCardia Systems, Inc. continues to set records with the implantation of the year's 150th SynCardia temporary Total Artificial Heart on Nov. 26, 2013.
CANCER RESEARCH UK scientists have developed a system to identify faulty or missing genes that could prevent specific chemotherapy regimes from working. This opens the doors for targeted breast cancer treatment, according to research published in the Lancet Oncology* today (Monday).
The new head of the Department of Veterans Affairs said Monday he is working to streamline the VA's sprawling bureaucracy, simplify the process for veterans to receive care and hire thousands of new doctors and nurses.
The anti-anginal medication ranolazine was shown to be safe in regard to certain outcomes but did not reduce the risk of major cardiovascular events such as death, heart attack or recurrent ischemia following acute coronary syndromes, according to a study in the April 25 issue of JAMA.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Elizabeth Bollenbacher, DO 417 State St, Ste 400, Bangor, ME 04401-6630 Ph: (207) 942-6096 | Elizabeth Bollenbacher, DO 417 State St, Ste 400, Bangor, ME 04401-6630 Ph: (207) 942-6096 |
News Archive
SynCardia Systems, Inc. continues to set records with the implantation of the year's 150th SynCardia temporary Total Artificial Heart on Nov. 26, 2013.
CANCER RESEARCH UK scientists have developed a system to identify faulty or missing genes that could prevent specific chemotherapy regimes from working. This opens the doors for targeted breast cancer treatment, according to research published in the Lancet Oncology* today (Monday).
The new head of the Department of Veterans Affairs said Monday he is working to streamline the VA's sprawling bureaucracy, simplify the process for veterans to receive care and hire thousands of new doctors and nurses.
The anti-anginal medication ranolazine was shown to be safe in regard to certain outcomes but did not reduce the risk of major cardiovascular events such as death, heart attack or recurrent ischemia following acute coronary syndromes, according to a study in the April 25 issue of JAMA.
› Verified 8 days ago
Eddy Karnabi, MD PHD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 1 Northeast Dr, Bangor, ME 04401 Phone: 207-275-3800 | |
Dr. Theodore William James, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 417 State St Ste 121, Bangor, ME 04401 Phone: 207-973-4266 | |
Fnu Kaleemullah, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 489 State St, Bangor, ME 04401 Phone: 207-973-7314 | |
Sverrir I Gunnarsson, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 1 Northeast Dr, Bangor, ME 04401 Phone: 207-275-3800 | |
Liga Yusvirazi, MD Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 360 Broadway, Bangor, ME 04401 Phone: 207-907-3283 | |
Ilsa Annetta Shulman, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 900 Broadway, Bangor, ME 04401 Phone: 207-907-3300 Fax: 207-907-1923 | |
Dr. Michael Paul Sighinolfi, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 360 Broadway Ste 100, Bangor, ME 04401 Phone: 207-907-3550 Fax: 207-907-3562 |